Exforge Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure - Exforge offers two of the most prescribed high blood pressure medicines in a convenient ...

(Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...

EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...

NEW YORK, Dec 28 (Reuters) - Novartis AG (NOVN.S), opens new tab said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in ...

Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The Swiss pharma will pay altogether $245 million in separate settlements with direct purchasers, ...

Novartis has been boosted by data from a new study which shows that its new combination antihypertensive Exforge lowers blood pressure in twice as many patients than those on amlodipine alone.

The FDA has approved Novartis‘ Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) tablets, a combination product containing a calcium channel blocker, an ...

Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge. The case ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Exforge HCT contains the active ingredients Amlodipine Besilate, ...

ZURICH, June 21 (Reuters) - Swiss drugmaker Novartis has received final U.S. approval for its high blood pressure medicine Exforge. Novartis said on Thursday that the U.S. Food and Drug Administration ...

NEW YORK (Reuters) -Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic ...